HAEMONETICS CORP SEC Filings

ABERNATHY ROBERT E reported acquisition or exercise transactions in this Form 4 filing.

Haemonetics Corp director Robert E. Abernathy received a grant of 2,538 restricted stock units (RSUs) on 2026-07-24 under the Amended and Restated 2019 Long-Term Incentive Compensation Plan. The RSUs vest 100% one year after grant, each into one share of common stock, bringing his direct holdings to 27,519 shares.

Haemonetics Corp reported that Martin D. Madaus serves as a director and is now identified as a reporting person for the company’s equity securities. The insider data shows no reported transactions, with 0 shares bought or sold and no derivative positions listed.

Haemonetics Corporation reported that its Board of Directors elected Martin Madaus as a director, effective July 24, 2026. He is expected to join the Audit Committee and the Governance and Compliance Committee and, as a non-employee director, will receive compensation consistent with the directors’ compensation program, including an annual equity award of approximately $200,000, and will enter into the company’s standard indemnification agreement.

At the 2026 annual meeting, shareholders holding 42,051,106 of 45,445,983 entitled shares were represented, a 92.53% quorum. Shareholders elected eight directors, approved on an advisory basis the compensation of named executive officers, and ratified Ernst & Young LLP as independent registered public accounting firm. They also approved amendments and restatements of the 2019 Long-Term Incentive Compensation Plan, authorizing 4,680,000 additional shares and extending its term through 2036, and the 2007 Employee Stock Purchase Plan, also extended through 2036.

Haemonetics Corporation is asking shareholders to elect eight directors, approve advisory say‑on‑pay, ratify Ernst & Young as auditor, and update its long‑term incentive and employee stock purchase plans at the 2026 Annual Meeting on July 24 in Boston.

The proxy highlights strong fiscal 2026 results: revenue of $1.334 billion, adjusted EPS of $4.96, free cash flow of $209.9 million and adjusted operating margin of 25.4%, including 9.5% organic ex‑CSL revenue growth and a 45.2% free cash flow increase. It notes robust shareholder support, with approximately 98.6% approval of 2026 executive pay, and explains a pay‑for‑performance program using cash bonuses tied to revenue, EPS and free cash flow plus PSU, RSU and option awards. The filing also details an independent, skills‑diverse board, a waiver of the age‑75 guideline to retain Board Chair Ellen Zane, strong governance practices such as majority voting and the right to call special meetings, and extensive shareholder outreach covering about 36% of shares.

Haemonetics Corp executive Maryanne Maunsell Farris, the VP and Chief Accounting Officer, reported an automatic share disposition tied to equity compensation. On the RSU vesting date, 259 shares of common stock were withheld at $71.28 per share to cover tax obligations, rather than sold on the open market. After this tax-withholding event, she beneficially owns 6,242 common shares, a figure that includes previously reported unvested restricted stock units.

Haemonetics Corp senior vice president of human resources Laurie A. Miller reported a small share disposition related to taxes. On the vesting of previously granted restricted stock units, 313 shares of common stock were withheld at a price of $71.28 per share to cover tax obligations. After this tax-withholding event, Miller directly holds 40,987 shares of Haemonetics common stock, which includes unvested restricted stock units.

Haemonetics Corporation is reorganizing how it reports its business segments. The company will move from three reportable segments to two, combining the Plasma and Blood Center segments into a single Apheresis segment and renaming the Hospital segment as MedSurg.

Haemonetics will begin reporting under this new structure with the first quarter of fiscal 2027, which began on March 29, 2026. To help comparison, it has posted a supplemental presentation with recast quarterly historical revenue for fiscal years 2024, 2025 and 2026, plus a recast of previously issued fiscal 2027 revenue guidance. The company explicitly states that this presentation does not reaffirm or update its fiscal 2027 guidance; any updates will come on the first quarter fiscal 2027 earnings call.

Haemonetics Corporation provides an overview of its global medical technology business in Plasma, Blood Center and Hospital segments, highlighting products that support plasma collection, blood management and hospital procedures.

The filing notes that Plasma and Hospital are viewed as the main long-term growth drivers, while Blood Center faces more challenging markets. In fiscal 2026, Plasma and Blood Center represented 39.3% and 16.6% of total revenue, and Hospital 44.1%. One Plasma customer generated 13% of total net revenues, and the ten largest customers accounted for 44%, underscoring customer concentration risk.

The company reports an aggregate market value of non‑affiliate equity of $2.23 billion as of September 27, 2025 and 45.4 million common shares outstanding as of May 15, 2026. Key themes include continued investment in R&D, new FDA clearances for NexSys PCS and VASCADE MVP XL, complex global regulatory obligations, supply chain and cybersecurity risks, and competition from large medtech peers across all business lines.